Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
| Revenue (Most Recent Fiscal Year) | $442.73M |
| Net Income (Most Recent Fiscal Year) | $-1.00B |
| PE Ratio (Current Year Earnings Estimate) | 20.87 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.83 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 18.91% |
| Net Margin (Trailing 12 Months) | -0.65% |
| Return on Equity (Trailing 12 Months) | -0.96% |
| Return on Assets (Trailing 12 Months) | 0.74% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.62 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.62 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-2.21 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.02 |
| Earnings per Share (Most Recent Fiscal Year) | $-6.27 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.03 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 160.03M |
| Free Float | 139.38M |
| Market Capitalization | $692.92M |
| Average Volume (Last 20 Days) | 2.40M |
| Beta (Past 60 Months) | 0.34 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.90% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |